CLINICAL TRIALS PROFILE FOR EXUBERA
✉ Email this page to a colleague
All Clinical Trials for Exubera
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00134147 ↗ | A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control | Completed | Sanofi | Phase 3 | 2005-04-01 | To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents |
| NCT00134147 ↗ | A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control | Completed | Pfizer | Phase 3 | 2005-04-01 | To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents |
| NCT00136916 ↗ | Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes | Terminated | Pfizer | Phase 3 | 2002-06-01 | This study is being done to find out the good and bad effects of inhaled insulin that is used by oral inhalation, to adult males and females with type 2 diabetes mellitus. The other name for this inhaled insulin is Exubera®. This study included a 2-year comparative treatment period followed by a 6-month follow-up period during which inhaled insulin-treated subjects were switched back to subcutaneous short-acting insulin. After this follow-up period, all eligible subjects entered a comparative extension period that was to last for 5 years. When the comparative portion of the study was terminated, all subjects were requested to return for a final extension follow-up month 3 visit. |
| NCT00137046 ↗ | Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes | Terminated | Pfizer | Phase 3 | 2002-05-01 | This study is being done to find out the good and bad effects of a drug that is not approved for sale and the effects if any on measures of pulmonary function in adult males and females with type 1 diabetes mellitus. The drug is called EXUBERA (inhaled insulin). This study included a 2-year comparative treatment period followed by a 6-month follow-up period during which inhaled insulin-treated subjects were switched back to subcutaneous short-acting insulin. After this follow-up period, all eligible subjects entered a comparative extension period that was to last for 5 years. When the comparative portion of the study was terminated, all subjects were requested to return for a final extension follow-up month 3 visit. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Exubera
Condition Name
Clinical Trial Locations for Exubera
Trials by Country
Clinical Trial Progress for Exubera
Clinical Trial Phase
Clinical Trial Sponsors for Exubera
Sponsor Name
